CRMD

Company Overview — What Does CorMedix Inc. Do?

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. CorMedix Inc. (CRMD) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joseph Todisco and employs approximately 30 people, headquartered in BEDMINSTER, New Jersey. With a market capitalization of $555M, CRMD is one of the notable companies in the Healthcare sector.

CorMedix Inc. (CRMD) Stock Rating — Reduce (April 2026)

As of April 2026, CorMedix Inc. receives a Reduce rating with a composite score of 39.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CRMD ranks #3,114 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CorMedix Inc. ranks #453 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRMD Stock Price and 52-Week Range

CorMedix Inc. (CRMD) currently trades at $7.22. The stock lost $0.14 (1.9%) in the most recent trading session. The 52-week high for CRMD is $17.43, which means the stock is currently trading -58.6% from its annual peak. The 52-week low is $5.60, putting the stock 28.9% above its annual trough. Recent trading volume was 637K shares, suggesting relatively thin trading activity.

Is CRMD Overvalued or Undervalued? — Valuation Analysis

CorMedix Inc. (CRMD) carries a value factor score of 80/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 3.88x, compared to the Healthcare sector average of 23.63x — a discount of 84%. The price-to-book ratio stands at 1.40x, versus the sector average of 2.75x. The price-to-sales ratio is 2.91x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CRMD trades at 6.46x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, CorMedix Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

CorMedix Inc. Profitability — ROE, Margins, and Quality Score

CorMedix Inc. (CRMD) earns a quality factor score of 34/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 36.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 17.7% versus the sector average of -33.1%.

On a margin basis, CorMedix Inc. reports gross margins of 93.6%, compared to 71.5% for the sector. The operating margin is 30.3% (sector: -66.1%). Net profit margin stands at 45.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12835.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRMD Debt, Balance Sheet, and Financial Health

CorMedix Inc. has a debt-to-equity ratio of 104.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.11x, indicating strong short-term liquidity. Total debt on the balance sheet is $4M. Cash and equivalents stand at $48M.

CRMD has a beta of 0.70, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CorMedix Inc. is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CorMedix Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CorMedix Inc. reported revenue of $195M and earnings per share (EPS) of $2.25. Net income for the quarter was $146M. Gross margin was 93.6%. Operating income came in at $88M.

In FY 2025, CorMedix Inc. reported revenue of $312M and earnings per share (EPS) of $2.25. Net income for the quarter was $163M. Gross margin was 88.5%. Revenue grew 617.0% year-over-year compared to FY 2024. Operating income came in at $150M.

In Q3 2025, CorMedix Inc. reported revenue of $104M and earnings per share (EPS) of $1.42. Net income for the quarter was $109M. Gross margin was 89.3%. Revenue grew 810.2% year-over-year compared to Q3 2024. Operating income came in at $51M.

In Q2 2025, CorMedix Inc. reported revenue of $40M and earnings per share (EPS) of $0.29. Net income for the quarter was $20M. Gross margin was 95.3%. Revenue grew 4829.4% year-over-year compared to Q2 2024. Operating income came in at $20M.

Over the past 8 quarters, CorMedix Inc. has demonstrated a growth trajectory, with revenue expanding from $806,119 to $195M. Investors analyzing CRMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRMD Dividend Yield and Income Analysis

CorMedix Inc. (CRMD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRMD Momentum and Technical Analysis Profile

CorMedix Inc. (CRMD) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

CRMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CorMedix Inc. (CRMD) ranks #453 out of 838 stocks based on the Blank Capital composite score. This places CRMD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRMD vs S&P 500 (SPY) comparison to assess how CorMedix Inc. stacks up against the broader market across all factor dimensions.

CRMD Next Earnings Date

No upcoming earnings date has been announced for CorMedix Inc. (CRMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRMD? — Investment Thesis Summary

The quantitative profile for CorMedix Inc. suggests caution. The quality score of 34/100 flags below-average profitability. The value score of 80/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, CorMedix Inc. (CRMD) earns a Reduce rating with a composite score of 39.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRMD stock.

Related Resources for CRMD Investors

Explore more research and tools: CRMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRMD head-to-head with peers: CRMD vs AZN, CRMD vs SLGL, CRMD vs VMD.